Literature DB >> 17512534

Fluorochrome-linked immunoassay for functional analysis of the mannose binding lectin complement pathway to the level of C3 cleavage.

Mary C Walsh1, Lisa A Shaffer, Benjamin J Guikema, Simon C Body, Stanton K Shernan, Amanda A Fox, Charles D Collard, Michael Fung, Ronald P Taylor, Gregory L Stahl.   

Abstract

The humoral response to invading pathogens is mediated by a repertoire of innate immune molecules and receptors able to recognize pathogen-associated molecular patterns. Mannose binding lectin (MBL) and ficolins are initiation molecules of the lectin complement pathway (LCP) that bridge innate and adaptive immunity. Activation of the MBL-dependent lectin pathway, to the level of C3 cleavage, requires functional MASP-2, C2, C4 and C3, all of which have been identified with genetic polymorphisms that can affect protein concentration and function. Current assays for MBL and MASP-2 lack the ability to assess activation of all components to the level of C3 cleavage in a single assay platform. We developed a novel, low volume, fluorochrome linked immunoassay (FLISA) that quantitatively assesses the functional status of MBL, MASP-2 and C3 convertase in a single well. The assay can be used with plasma or serum. Multiple freeze/thaw cycles of serum do not significantly alter the assay, making it ideal for high throughput of large sample databases with minimal volume use. The FLISA can be used potentially to identify specific human disease correlations between these components and clinical outcomes in already established databases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512534      PMCID: PMC1976379          DOI: 10.1016/j.jim.2007.04.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  53 in total

1.  Association of mannose-binding-lectin deficiency with severe atherosclerosis.

Authors:  H O Madsen; V Videm; A Svejgaard; J L Svennevig; P Garred
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321

2.  The level of mannan-binding protein regulates the binding of complement-derived opsonins to mannan and zymosan at low serum concentrations.

Authors:  M Super; R J Levinsky; M W Turner
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

3.  Preparation of monoclonal antibodies to C3b by immunization with C3b(i)-sepharose.

Authors:  L Tosic; W M Sutherland; J Kurek; J C Edberg; R P Taylor
Journal:  J Immunol Methods       Date:  1989-06-21       Impact factor: 2.303

4.  Association of familial deficiency of mannose-binding lectin and meningococcal disease.

Authors:  W A Bax; O J Cluysenaer; A K Bartelink; P C Aerts; R A Ezekowitz; H van Dijk
Journal:  Lancet       Date:  1999-09-25       Impact factor: 79.321

5.  Association of mannose binding lectin (MBL) gene polymorphism and serum MBL concentration with characteristics and progression of systemic lupus erythematosus.

Authors:  R Takahashi; A Tsutsumi; K Ohtani; Y Muraki; D Goto; I Matsumoto; N Wakamiya; T Sumida
Journal:  Ann Rheum Dis       Date:  2005-02       Impact factor: 19.103

6.  Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy.

Authors:  M Endo; H Ohi; I Ohsawa; T Fujita; M Matsushita; T Fujita
Journal:  Nephrol Dial Transplant       Date:  1998-08       Impact factor: 5.992

7.  Binding of mannan-binding protein to various bacterial pathogens of meningitis.

Authors:  L C van Emmerik; E J Kuijper; C A Fijen; J Dankert; S Thiel
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

8.  A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus.

Authors:  M A Seelen; E A van der Bijl; L A Trouw; T C M Zuiverloon; J R Munoz; F C Fallaux-van den Houten; N Schlagwein; M R Daha; T W J Huizinga; A Roos
Journal:  Rheumatology (Oxford)       Date:  2004-10-12       Impact factor: 7.580

9.  Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein.

Authors:  H O Madsen; P Garred; S Thiel; J A Kurtzhals; L U Lamm; L P Ryder; A Svejgaard
Journal:  J Immunol       Date:  1995-09-15       Impact factor: 5.422

10.  Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk.

Authors:  Saedis Saevarsdottir; Oskar Orn Oskarsson; Thor Aspelund; Gudny Eiriksdottir; Thora Vikingsdottir; Vilmundur Gudnason; Helgi Valdimarsson
Journal:  J Exp Med       Date:  2004-12-28       Impact factor: 14.307

View more
  9 in total

1.  Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications.

Authors:  Vasile I Pavlov; Laura R La Bonte; William M Baldwin; Maciej M Markiewski; John D Lambris; Gregory L Stahl
Journal:  Am J Pathol       Date:  2011-11-08       Impact factor: 4.307

2.  The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart.

Authors:  Laura R La Bonte; Betsy Dokken; Grace Davis-Gorman; Gregory L Stahl; Paul F McDonagh
Journal:  Diab Vasc Dis Res       Date:  2009-07       Impact factor: 3.291

3.  Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis.

Authors:  Laura R La Bonte; Vasile I Pavlov; Ying S Tan; Kazue Takahashi; Minoru Takahashi; Nirmal K Banda; Chenhui Zou; Teizo Fujita; Gregory L Stahl
Journal:  J Immunol       Date:  2011-12-12       Impact factor: 5.422

4.  Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

Authors:  Laura Evgin; Sergio A Acuna; Christiano Tanese de Souza; Monique Marguerie; Chantal G Lemay; Carolina S Ilkow; C Scott Findlay; Theresa Falls; Kelley A Parato; David Hanwell; Alyssa Goldstein; Roberto Lopez; Sandra Lafrance; Caroline J Breitbach; David Kirn; Harold Atkins; Rebecca C Auer; Joshua M Thurman; Gregory L Stahl; John D Lambris; John C Bell; J Andrea McCart
Journal:  Mol Ther       Date:  2015-03-25       Impact factor: 11.454

5.  Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis.

Authors:  Vasile I Pavlov; Mikkel-Ole Skjoedt; Ying Siow Tan; Anne Rosbjerg; Peter Garred; Gregory L Stahl
Journal:  Circulation       Date:  2012-10-02       Impact factor: 29.690

6.  Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model.

Authors:  Vasile I Pavlov; Ying S Tan; Erin E McClure; Laura R La Bonte; Chenhui Zou; William B Gorsuch; Gregory L Stahl
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

7.  Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure.

Authors:  Tea L Laursen; Thomas D Sandahl; Sidsel Støy; Frank V Schiødt; William M Lee; Hendrik Vilstrup; Steffen Thiel; Henning Grønbaek
Journal:  Liver Int       Date:  2014-09-30       Impact factor: 5.828

8.  Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.

Authors:  Masayuki Ozaki; Yulin Kang; Ying Siow Tan; Vasile I Pavlov; Bohan Liu; Daniel C Boyle; Rafail I Kushak; Mikkel-Ole Skjoedt; Eric F Grabowski; Yasuhiko Taira; Gregory L Stahl
Journal:  Kidney Int       Date:  2016-07-01       Impact factor: 10.612

Review 9.  Complement activation and cardiac surgery: a novel target for improving outcomes.

Authors:  Gregory L Stahl; Stanton K Shernan; Peter K Smith; Jerrold H Levy
Journal:  Anesth Analg       Date:  2012-07-13       Impact factor: 5.108

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.